What is Lixte Biotechnology Holdings, Inc.'s earnings per share (EPS)?

Lixte Biotechnology Holdings, Inc. (LIXT) reported diluted earnings per share of -$1.26 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Lixte Biotechnology Holdings, Inc. (LIXT) Financials

LIXT

FY2025 annual

Revenue Not reported for FY2025

Net Income -$6.1M -69.5% YoY

EPS (Diluted) -$1.26 YoY not available

Operating Cash Flow -$3.1M +3.0% YoY

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2026, ended Mar 31, 2026 Reported May 14, 2026 Currency USD FYE December

Newest figures come from the 10-K for Q1 FY2026, filed May 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the LIXT SEC filings page.

This page shows Lixte Biotechnology Holdings, Inc. (LIXT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI LIXT FY2025 2026-10-03

Nomad remains funded by capital injections while losses persist, with cash use improving less than accounting results suggest.

The net loss widened to $6.1M in FY2025, but operating cash flow improved to -$3.1M despite that accounting deterioration. This gap indicates the earnings decline did not translate one-for-one into cash consumption, pointing to non-cash or timing effects rather than a matching increase in cash use.

The 2025 balance-sheet expansion was funded chiefly by a $10.3M financing inflow while operating cash flow remained negative; this describes a capital-dependent funding model rather than internally financed operations.

Reported liquidity equaled 20 months of the latest annual operating outflow, and the 3.9x current ratio shows current assets exceeded current liabilities at year-end. That near-term cushion coexisted with a net loss and negative operating cash flow, so liquidity and profitability are telling different stories.

Financial Health Signals

Financial health score not available

Lixte Biotechnology Holdings, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

3/6

Lixte Biotechnology Holdings, Inc. passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

Lixte Biotechnology Holdings, Inc. reported a net loss of $6.1M while operations used $3.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Lixte Biotechnology Holdings, Inc. reported an operating loss of $5.1M against $9K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Net Income

-$2.0M

YoY-180.1%

Lixte Biotechnology Holdings, Inc. reported -$2.0M in net income in Q1 2026. This represents a decrease of 180.1% from the same quarter a year earlier.

EPS (Diluted)

-$0.18

Lixte Biotechnology Holdings, Inc. earned -$0.18 per diluted share (EPS) in Q1 2026.

Revenue

Not reported for Q1 2026.

EBITDA

Not reported for Q1 2026.

Cash & Balance Sheet

Cash & Debt

$3.3M

YoY+134.8%

QoQ-36.3%

5Y CAGR-15.9%

10Y CAGR+41.7%

Lixte Biotechnology Holdings, Inc. held $3.3M in cash as of Q1 2026; long-term debt is not reported for that period.

Shares Outstanding

12M

QoQ+32.2%

5Y CAGR-3.0%

10Y CAGR-13.2%

Lixte Biotechnology Holdings, Inc. had 12M shares outstanding in Q1 2026. Against the prior quarter it is up 32.2%.

Free Cash Flow

Not reported for Q1 2026.

Dividends Per Share

Not reported for Q1 2026.

Margins & Returns

Return on Equity

-25.0%

YoY+36.2pp

Lixte Biotechnology Holdings, Inc.'s ROE was -25.0% in Q1 2026, measuring profit generated per dollar of shareholder equity. This is up 36.2 percentage points from the same quarter a year earlier.

Gross Margin

Not reported for Q1 2026.

Operating Margin

Not reported for Q1 2026.

Net Margin

Not reported for Q1 2026.

Capital Allocation

R&D Spending

$333K

YoY+264.5%

Lixte Biotechnology Holdings, Inc. invested $333K in research and development in Q1 2026. This represents an increase of 264.5% from the same quarter a year earlier.

Share Buybacks

Not reported for Q1 2026.

Capital Expenditures

Not reported for Q1 2026.

LIXT Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LIXT quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$200K	N/A	$0	$0	$0
R&D Expenses	N/A	$255K-64.9%	$726K-19.1%	$898K-33.4%	$1.3M-22.3%	$1.7M+41.9%	$1.2M+49.1%	$821K+1916.8%	$41K-91.3%	$467K-46.3%	$870K-58.4%	$2.1M+87.1%	$1.1M+27.1%	$880K-13.1%	$1.0M-24.2%	$1.3M
SG&A Expenses	N/A	$4.9M+70.5%	$2.8M-32.1%	$4.2M+64.6%	$2.5M-15.8%	$3.0M+295.3%	$765K-54.2%	$1.7M-20.4%	$2.1M+56.2%	$1.3M+6.1%	$1.3M+67.7%	$754K-41.3%	$1.3M+159.7%	$495K-54.7%	$1.1M+105.0%	$533K
Operating Income	N/A	-$5.1M-43.0%	-$3.6M+29.8%	-$5.1M+19.3%	-$6.3M+6.1%	-$6.7M-105.7%	-$3.3M-31.2%	-$2.5M-16.5%	-$2.1M-18.1%	-$1.8M+15.2%	-$2.1M+19.3%	-$2.6M-10.1%	-$2.4M-74.8%	-$1.4M+34.7%	-$2.1M-12.7%	-$1.9M
EBITDA	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$1.4M+34.7%	-$2.1M-12.7%	-$1.9M
Interest Expense	N/A	$9K-45.6%	$17K+3.6%	$16K+82.9%	$9K+19.7%	$7K+101.8%	$4K	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0	$0
Income Tax	N/A	$2K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$6.1M-69.5%	-$3.6M+29.5%	-$5.1M+19.4%	-$6.3M+6.2%	-$6.7M-106.1%	-$3.3M-33.8%	-$2.4M-14.4%	-$2.1M-18.0%	-$1.8M+15.3%	-$2.1M+25.2%	-$2.9M	N/A	-$1.4M+61.6%	-$3.6M-73.1%	-$2.1M
EPS (Basic)	N/A	N/A	-$1.59+40.2%	-$2.66+33.3%	-$3.99-698.0%	-$0.50	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	—	-$1.26	-$1.59+40.2%	-$2.66+33.3%	-$3.99	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	5M	2M+17.4%	2M+21.1%	2M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'2610-K	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'25	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
R&D Expenses	$333K+264.5%	N/A	$51K-86.0%	$61K-71.2%	$91K-23.2%	N/A	$362K+173.0%	$211K-50.7%
SG&A Expenses	$1.7M+168.7%	N/A	$1.8M+181.6%	$714K-10.6%	$615K-27.4%	N/A	$622K+74.6%	$798K+52.8%
Operating Income	-$2.0M-181.1%	N/A	-$1.8M-83.2%	-$775K+23.2%	-$707K+26.9%	N/A	-$983K+4.0%	-$1.0M+39.6%
Interest Expense	$3K-1.2%	N/A	$457-56.4%	$2K-56.4%	$3K-56.4%	N/A	$1K+276.0%	$4K+113.2%
Net Income	-$2.0M-180.1%	N/A	-$2.0M-100.8%	-$776K+23.3%	-$710K+26.9%	N/A	-$986K+3.2%	-$1.0M+39.4%
EPS (Basic)	-$0.18+37.9%	N/A	-$0.33+25.0%	-$0.29+35.6%	-$0.29+32.6%	N/A	-$0.44+10.2%	-$0.45+55.0%
EPS (Diluted)	-$0.18	N/A	-$0.33	-$0.29	-$0.29+32.6%	N/A	-$0.44+10.2%	-$0.45+55.0%
Diluted Shares (Avg)	11M	N/A	6M	3M	2M+9.9%	N/A	2M+8.4%	2M+35.0%

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA, Income Tax.

LIXT Balance Sheet

LIXT quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Total Assets	$12.7M+1011.6%	$1.1M-73.4%	$4.3M-22.5%	$5.6M+9.2%	$5.1M-2.6%	$5.2M+95.7%	$2.7M-38.4%	$4.3M+217.0%	$1.4M+215.7%	$433K-27.5%	$598K+10.9%	$539K-3.4%	$558K-68.2%	$1.8M+307.9%	$430K
Current Assets	$5.2M+352.1%	$1.1M-73.4%	$4.3M-22.5%	$5.6M+9.2%	$5.1M-2.6%	$5.2M+95.7%	$2.7M-38.4%	$4.3M+216.8%	$1.4M+215.7%	$433K-27.5%	$598K+10.9%	$539K-3.4%	$558K-68.2%	$1.8M+307.9%	$430K
Cash & Equivalents	$5.1M+391.5%	$1.0M-75.3%	$4.2M-21.5%	$5.4M+11.0%	$4.8M-4.8%	$5.1M+95.1%	$2.6M-39.2%	$4.3M+227.2%	$1.3M+553.1%	$200K+690.8%	$25K-43.1%	$44K-90.7%	$475K-71.3%	$1.7M+11473.5%	$14K
Short-Term Investments	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Investments	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.8M+456.8%	$318K+1.4%	$314K-20.7%	$396K+30.6%	$303K+39.9%	$217K-9.0%	$238K+12.8%	$211K-43.5%	$373K+70.6%	$219K-23.5%	$286K+4.5%	$273K-15.0%	$322K+23.2%	$261K-25.5%	$351K
Current Liabilities	$1.3M+318.8%	$318K+1.4%	$314K-20.7%	$396K+30.6%	$303K+39.9%	$217K-9.0%	$238K+12.8%	$211K-43.5%	$373K+70.6%	$219K-23.5%	$286K+4.5%	$273K-15.0%	$322K+23.2%	$261K-25.5%	$351K
Non-Current Liabilities	$439K	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Equity	$9.7M+1068.3%	$827K-79.3%	$4.0M-22.7%	$5.2M+7.8%	$4.8M-4.4%	$5.0M+105.9%	$2.4M-41.0%	$4.1M+314.6%	$995K+363.3%	$215K-31.2%	$312K+17.5%	$266K+12.5%	$236K-84.2%	$1.5M+1787.9%	$79K
Retained Earnings	-$58.1M-11.5%	-$52.1M-7.4%	-$48.5M-11.7%	-$43.4M-17.0%	-$37.1M-22.2%	-$30.4M-12.1%	-$27.1M-9.9%	-$24.6M-9.5%	-$22.5M-8.7%	-$20.7M-11.5%	-$18.6M-18.2%	-$15.7M-21.4%	-$13.0M	N/A	N/A

Metric	Q1'2610-K	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'25	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Total Assets	$10.9M+617.5%	$12.7M+1011.6%	$5.4M+220.4%	$1.2M-55.4%	$1.5M-57.8%	$1.1M-73.4%	$1.7M-67.6%	$2.7M-13.8%
Current Assets	$3.4M	$5.2M+352.1%	$5.4M+221.7%	$990K-62.9%	N/A	$1.1M-73.4%	$1.7M-67.7%	$2.7M-13.8%
Cash & Equivalents	$3.3M+134.8%	$5.1M+391.5%	$2.9M+76.3%	$887K-65.8%	$1.4M-59.4%	$1.0M-75.3%	$1.6M-67.9%	$2.6M-10.9%
Total Liabilities	$1.7M+375.0%	$1.8M+456.8%	$521K+58.5%	$537K+27.4%	$355K-23.3%	$318K+1.4%	$329K+5.5%	$421K+4.7%
Current Liabilities	$1.2M+245.0%	$1.3M+318.8%	$521K+58.5%	$537K+27.4%	$355K-23.3%	$318K+1.4%	$329K+5.5%	$421K+4.7%
Non-Current Liabilities	$462K	$439K	$0	$0	$0	$0	$0	$0
Total Equity	$7.9M+585.4%	$9.7M+1068.3%	$4.9M+259.4%	$651K-71.0%	$1.2M-62.9%	$827K-79.3%	$1.4M-72.2%	$2.2M-16.6%
Retained Earnings	-$60.0M-13.7%	-$58.1M-11.5%	-$55.5M-7.9%	-$53.6M-6.1%	-$52.8M-6.7%	-$52.1M-7.4%	-$51.4M-8.4%	-$50.5M-8.7%

Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Accounts Receivable, Long-Term Investments, Goodwill, Long-Term Debt.

LIXT Cash Flow Statement

LIXT quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Cash Flow	-$4.3M	-$3.1M+3.0%	-$3.2M+26.3%	-$4.3M+6.9%	-$4.6M-11.3%	-$4.1M-94.4%	-$2.1M-227.3%	$1.7M+210.8%	-$1.5M-7.0%	-$1.4M+15.8%	-$1.7M+23.1%	-$2.2M-33.4%	-$1.6M-38.6%	-$1.2M+2.1%	-$1.2M+11.3%	-$1.4M
Depreciation & Amortization	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0	$0
Stock-Based Compensation	N/A	$1.4M+231.8%	$418K-45.9%	$773K-50.0%	$1.5M-40.5%	$2.6M+107.7%	$1.3M+67.1%	$749K-4.7%	$786K+1011.3%	$71K-75.4%	$287K-47.8%	$550K-41.9%	$946K+693.4%	$119K	N/A	N/A
Investing Cash Flow	N/A	-$3.2M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$104K-5.0%	$110K+152.8%	-$208K-20756300.0%	-$1-100.0%	$345K-72.4%	$1.2M
Financing Cash Flow	$10.3M	$10.3M	N/A	$3.1M-38.9%	$5.1M+31.9%	$3.9M-15.3%	$4.6M	N/A	$4.5M+77.9%	$2.5M+44.1%	$1.7M-14.8%	$2.1M+45.3%	$1.4M	$0-100.0%	$2.5M+49931.7%	$5K
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$25K	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'2610-K	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'25	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Operating Cash Flow	-$1.8M-222.1%	-$1.1M-81.7%	-$927K+3.2%	-$487K+40.5%	-$568K+28.0%	-$599K+33.6%	-$958K-1.4%	-$819K+30.3%
Stock-Based Compensation	$82K-17.6%	N/A	$777K+627.0%	$268K+105.1%	$100K-3.1%	N/A	$107K-4.7%	$131K-53.3%
Investing Cash Flow	-$25K	-$535K	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$914K0.0%	$3.8M	$5.6M	-$10K	$914K	N/A	N/A	N/A

Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

LIXT Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LIXT quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-1323.2%	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-1426.0%	N/A	N/A	N/A	N/A
Return on Equity	-62.9%+370.6pp	-433.5%-306.2pp	-127.3%-5.1pp	-122.2%+18.3pp	-140.5%-75.3pp	-65.1%+35.1pp	-100.3%-48.6pp	-51.7%+130.0pp	-181.7%+812.3pp	-994.0%-80.8pp	-913.2%	N/A	-581.9%-342.0pp	-239.9%+2377.0pp	-2617.0%
Return on Assets	-47.7%+265.3pp	-313.1%-195.0pp	-118.1%-4.6pp	-113.5%+18.6pp	-132.1%-69.7pp	-62.4%+28.9pp	-91.3%-42.1pp	-49.2%+83.0pp	-132.2%+360.3pp	-492.5%-15.6pp	-477.0%	N/A	-246.4%-42.2pp	-204.2%+277.0pp	-481.2%
Current Ratio	3.88+0.3x	3.60-10.1x	13.73-0.3x	14.05-2.8x	16.81-7.3x	24.15+12.9x	11.23-9.3x	20.55+16.9x	3.67+1.7x	1.98-0.1x	2.09+0.1x	1.97+0.2x	1.73-5.0x	6.71+5.5x	1.23
Debt-to-Equity	0.18-0.2x	0.38+0.3x	0.080.0x	0.080.0x	0.060.0x	0.04-0.1x	0.100.0x	0.05-0.3x	0.37-0.6x	1.02+0.1x	0.91-0.1x	1.03-0.3x	1.36+1.2x	0.18-4.3x	4.44
Asset Turnover	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	0.33	N/A	0.000.0x	0.000.0x	0.00

Metric	Q1'2610-K	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'25	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Return on Equity	-25.0%+36.2pp	N/A	-40.3%+31.8pp	-119.1%-74.1pp	-61.2%-30.1pp	N/A	-72.1%-51.4pp	-45.0%+17.0pp
Return on Assets	-18.3%+28.6pp	N/A	-36.4%+21.7pp	-65.3%-27.4pp	-46.9%-19.8pp	N/A	-58.1%-38.7pp	-37.9%+16.0pp
Current Ratio	2.78	3.88+0.3x	10.42+5.3x	1.84-4.5x	N/A	3.60-10.1x	5.13-11.7x	6.33-1.4x
Debt-to-Equity	0.21-0.1x	0.18-0.2x	0.11-0.1x	0.82+0.6x	0.31+0.2x	0.38+0.3x	0.24+0.2x	0.190.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Lixte Biotechnology Holdings, Inc. LIXT	FY2025	N/A	-$6.1M	N/A	$125.4M	—
Akari Therapeutics plc AKTX	FY2025	N/A	-$17.3M	N/A	$20.4M	—
Q32 Bio Inc. QTTB	FY2025	$53.7M	$29.8M	55.5%	$249.2M	67/100
Boundless Bio, Inc. BOLD	FY2025	N/A	-$58.2M	N/A	$59.1M	—
Propanc Biopharma, Inc. PPCB	FY2026	N/A	-$18.9M	N/A	$3.2M	—
Allarity Therapeutics, Inc. ALLR	FY2025	$320K	-$11.2M	N/A	$15.9M	—

Where Lixte Biotechnology Holdings, Inc. Ranks

Frequently Asked Questions

Is Lixte Biotechnology Holdings, Inc. profitable?

No, Lixte Biotechnology Holdings, Inc. (LIXT) reported a net income of -$6.1M in fiscal year 2025.

What is Lixte Biotechnology Holdings, Inc.'s return on equity (ROE)?

Lixte Biotechnology Holdings, Inc. (LIXT) has a return on equity of -62.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Lixte Biotechnology Holdings, Inc.'s operating cash flow?

Lixte Biotechnology Holdings, Inc. (LIXT) recorded an outflow of $3.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Lixte Biotechnology Holdings, Inc.'s total assets?

Lixte Biotechnology Holdings, Inc. (LIXT) had $12.7M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Lixte Biotechnology Holdings, Inc. spend on research and development?

Lixte Biotechnology Holdings, Inc. (LIXT) invested $255K in research and development during fiscal year 2025.

How many shares does Lixte Biotechnology Holdings, Inc. have outstanding?

Lixte Biotechnology Holdings, Inc. (LIXT) had 9M shares outstanding as of fiscal year 2025.

What is Lixte Biotechnology Holdings, Inc.'s current ratio?

Lixte Biotechnology Holdings, Inc. (LIXT) had a current ratio of 3.88 as of fiscal year 2025, which is generally considered healthy.

What is Lixte Biotechnology Holdings, Inc.'s debt-to-equity ratio?

Lixte Biotechnology Holdings, Inc. (LIXT) had a debt-to-equity ratio of 0.18 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Lixte Biotechnology Holdings, Inc.'s return on assets (ROA)?

Lixte Biotechnology Holdings, Inc. (LIXT) had a return on assets of -47.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does Lixte Biotechnology Holdings, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Lixte Biotechnology Holdings, Inc. (LIXT) held $5.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $3.1M over that year. Dividing the one by the other, the reported balance equals about 20 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Lixte Biotechnology Holdings, Inc.'s Piotroski F-Score?

Lixte Biotechnology Holdings, Inc. (LIXT) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Lixte Biotechnology Holdings, Inc.'s earnings high quality?

Lixte Biotechnology Holdings, Inc. (LIXT) reported a net loss of $6.1M while operations used $3.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Lixte Biotechnology Holdings, Inc. cover its interest payments?

Lixte Biotechnology Holdings, Inc. (LIXT) reported an operating loss of $5.1M against $9K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.